33 results
8-K
EX-99.2
hh9oq9gskfyfh
6 May 21
Aravive continues to expand development of AVB-500 in multiple indications and combination treatments with first-line treatment for pancreatic cancer
7:08am
8-K
EX-99.2
13csydeebf 5cn
27 Apr 21
Aravive Announces First Patient Dosed in Phase 3 Registrational Trial Evaluating AVB-500 in Patients with Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-99.1
3earu5
2 Mar 21
Regulation FD Disclosure
8:00am
8-K
EX-99.2
vhmwcs6
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
8-K
EX-10.1
qadfn i7ja
10 Nov 20
Entry into a Material Definitive Agreement
7:10am
8-K
EX-1.1
fq1hl9mo
27 Nov 19
Aravive Announces Proposed Public Offering of Common Stock
4:15pm
8-K
EX-99.1
mw9uf syg5krw6l5
12 Aug 19
Other Events
7:05am
8-K
EX-1.1
kp8vphkvblbs nb147vl
26 Mar 19
Entry into a Material Definitive Agreement
6:07am